No actionable trading signal. This is a routine PDMR share sale disclosure with no bearing on GSK's fundamentals. Monitor for any cluster of insider sales or changes in executive shareholding patterns in future filings.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $52.07entry
- T+1 · 4mo ago −0.73%α −1.44% · $51.69
- T+5 · 3mo ago +0.19%α −3.43% · $52.17
- T+20 · 3mo ago −3.46%α −7.42% · $50.27
- T+60 · 25d ago −2.54%α −5.00% · $50.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine 6-K disclosing that President of Global Supply Chain Regis Simard sold 38,000 ordinary shares at £20.38 on July 29, 2026. The sale is a single PDMR transaction with no material financial impact on the company. This filing is administrative in nature and does not signal any change in GSK's business operations or financial health.
Key Facts
- President of Global Supply Chain Regis Simard sold 38,000 ordinary shares on July 29, 2026
- Sale price was £20.38 per share
- Transaction executed on the London Stock Exchange (XLON)
- Filing is a standard PDMR transaction notification under UK rules
Financial Impact
Sale of 38,000 shares at £20.38 totals approximately £774,440, immaterial relative to GSK's $107.8B market cap
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (GSK), Batch item 1 | 0001654954-26-007005 |
| Document: 0001654954-26-007005-index-headers.html | 0001654954-26-007005 |
| Document: 0001654954-26-007005-index.html | 0001654954-26-007005 |
| Document: 0001654954-26-007005.txt | 0001654954-26-007005 |
| 6-K Filing (GSK), Batch item 5 | 0001654954-26-007005 |
| Document: 0001654954-26-007005-index-headers.html | 0001654954-26-007005 |
| Document: 0001654954-26-007005-index.html | 0001654954-26-007005 |
| Document: 0001654954-26-007005.txt | 0001654954-26-007005 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers